Genta (company)

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Genta, Inc.
Traded as OTCQB: GNTA
Industry Biotechnology
Headquarters Berkeley Heights, New Jersey
Website www.genta.com

Genta Inc. was a biopharmaceutical company based in Berkeley Heights, New Jersey, United States, which develops products for the treatment of patients with cancer. In August 2012 the company filed for bankruptcy.

Products[edit]

Its products include:

  • Genasense (development stage anticancer oblimersen sodium injection) [1]
  • Tesetaxel (development stage anticancer oral tubulin inhibitor)
  • Ganite (Genta's only U.S. Food and Drug Administration (FDA) approved drug, is a gallium nitrate injection for treatment of cancer-related hypercalcemia)

Financial record[edit]

In addition to financing agreements with institutional investors, through its history, Genta Inc., like most listed unprofitable development stage start ups, has made reverse stock splits and stock dilution in order to get financial resources and stay afloat. For example, in July 2009, the company implemented a reverse stock split, which replaced 50 old shares with one new share.[2]

References[edit]

  1. ^ Feuerstein, Adam (October 29, 2009). "Genta Melanoma Drug Study Disappoints: BioBuzz". TheStreet.com. Retrieved 10 January 2010. 
  2. ^ "Genta Implements Reverse Stock Split New Trading Symbol is "GETA"". Press Release (Genta Inc.). July 13, 2009. Retrieved 10 January 2010. [dead link]

External links[edit]

Official website

Coordinates: 40°39′50″N 74°24′53″W / 40.6638°N 74.4148°W / 40.6638; -74.4148